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Aim: The aim of the presented article was investigation of anticancer efficacy of hydroxyethylthiamine diphosphate (HTD) in vivo. 
Materials and Methods: The study was carried out on 30 C57BL/6J mice subcutaneously transplanted with Ehrlich carcinoma. 
Animals were treated with intraperitoneal injections of the solution composed from pyruvic acid and thiamine bromide every other 
day during 10 days and thereafter, every day during 2 weeks. Treatment efficacy was evaluated by tumor growth inhibition. Results: 
In experimental animals treated with HTD, significant tumor growth inhibition has been registered: 73% at day 45th compared 
to the control group (p < 0.001). Conclusion: Treatment with HTD demonstrated high anticancer efficacy in vivo.
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As it is known, the tumor tissue is composed of atypi-
cal cells with unlimited cell proliferation potential re-
questing great amount of energy. Therefore, oncoge-
nesis should require alterations in energetic apparatus 
of cell, i.e. in electron-transport chain of mitochondria. 
We suppose that alterations in electron-transport chain 
of mitochondria may depend on cytochrome structure 
(involved in normal functioning of respiratory system), 
and increased pH in mitochondria, which could affect 
normal functioning of some enzymes, in particular, py-
ruvate dehydrogenase, an enzyme involved in the first 
reaction of oxidative decarboxylation of pyruvic acid, 
where coenzyme is thiamine diphosphate (TDP). TDP 
activity depends on pH of medium [1]. TDP is active 
at low pH level, i.e. in acidic medium, and its activity 
(oxidative decarboxylation of pyruvic acid) decreases 
in neutral or alkaline medium. Upon further shift of mi-
tochondrial pH, the aerobic glycolysis may be replaced 
by anaerobic glycolysis.
In present study we aimed to evaluate the effects 
of hydroxyethylthiamine diphosphate (HTD) adminis-
tration on tumor growth in vivo.
Experiments were carried out on 30 C57BL/6J 
male mice, 2–3 months old and with body weight 
of 18–20 g. All animals were fed standard laboratory 
chow and given free access to water. The care and use 
of the animals complied with the Georgian regulations 
on protection of animals, with Guidelines prepared 
by the Ethics Committee of the Institutional Animal 
Care and with the National Institutes of Health Guide 
for the Care and Use of Laboratory animals.
All experimental animals were subjected to sub-
cutaneous inoculations with Ehrlich carcinoma cells 
(1•106 cells). Thereafter, they were randomly divided 
into 2 groups: group 1 was control (untreated mice), 
and group 2 was experimental, where mice were sub-
jected to intraperitoneal injections with 0.2 ml of mixture 
prepared as follows: 0.1 ml of 98% pyruvic acid were 
diluted with distilled water 1000 times, and 5 mg thia-
mine bromide was added. Injections of the preparation 
were started on the 14th day of tumor growth. Tumor 
volume was measured every 3rd day of cancer growth. 
Initially, during the first 10 days injections were carried 
out every other day, and thereafter — every day, du-
ring 2 weeks.
Treatment efficacy was evaluated by calculating 
tumor growth inhibition (%) by the formula:
Vcontr. − Vexp./Vcontr.•100
Obtained data were analyzed statistically with 
the use of SPSS 16.0 for Windows. Significance of dif-
ferences between the data were determined by using 
the Student’s t-test. The criterion for significance was 
set to p < 0.05.
Results of experiments have shown that HTD treat-
ment resulted in significant inhibition of tumor growth 
(Table).
Table. Tumor volumes and tumor growth inhibition in control (group 1) and 
experimental (group 2) mice treated with HDT
Day Tumor volume, mm
3
Group 1 Group 2 TGI, %
18th 589 ± 50.5 463 ± 64.6 21
21st 865 ± 46.6 723 ± 88.5 16
24th 1156 ± 80.4 805 ± 90.0* 30
27th 1874 ± 299.8 854 ± 121.4** 54
30th 2325 ± 354.9 962 ± 151.0** 59
33rd 2445 ± 277.3 1448 ± 398.5 41
36th 3316 ± 326.8 2224 ± 618.1 33
39th 5453 ± 791.4 1611 ± 453.9*** 70
42nd 5539 ± 861.1 1634 ± 459.9** 71
45th 5374 ± 102.5 1425 ± 397.5*** 73
Notes: the difference is significant compared to the control: * p < 0.01; 
**p < 0.005; ***p < 0.001.
At the beginning (18th and 21st days of tumor growth) 
in case of every other day treatment regimen, the TGI 
in HTD-treated mice 2 was not statistically significant, 
but at 24th day TGI was 30% (p < 0.01). TGI was higher 
and significant when injections were carried out every 
day (at 27th, 30th, 39th, 42nd and 45th days).
Supposedly, administration of HTD restores oxida-
tive decarboxylation of pyruvic acid, Krebs cycle and 
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functioning of electron-transport chain of mitochon-
dria. Therefore, energy production in malignant cells 
normalizes and cell proliferation decreases.
Experiments carried out in different countries refer-
ring on biological reactions proceeding in mitochondria 
are somehow similar (not same) to our investigations. 
For instance, in literature there is information about 
antitumor efficacy of dichloroacetate in glioblastoma 
treatment, and 3-bromopyruvate acid in experimental 
liver cancer [2, 3]. However, information about admi-
nistration of HTD as an anticancer agent has not been 
found up today in the available literature.
Although HTD revealed anticancer efficacy and 
administration of HTD in Ehrlich carcinoma bearing 
C57BL/6J mice caused significant inhibition of can-
cer growth, these results support the need of a further 
detailed investigation of HTD anticancer properties with 
the final aim of its possible use as therapeutic agent.
REFERENCES
1. Devlin T. Sources and fates of acetyl coenzyme A. Text-
book of Biochemistry with clinical correlations. 7th edition. 
2010; 548–52.
2. Michelakis E, Sutendra G, Dromparis P, et al. Metabolic 
modulation of glioblastoma with dichloroacetate. Sci Transl 
Med 2010; 2: 34–9.
3. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradi-
cation in all cases using 3-bromopyruvate therapy to deplete 
ATP. Biochem Biophys Res Commun 2004; 324: 269–75.
 Copyright © Experimental Oncology, 2014 
